WO2007114262A1 - カゼインナノ粒子 - Google Patents
カゼインナノ粒子 Download PDFInfo
- Publication number
- WO2007114262A1 WO2007114262A1 PCT/JP2007/056893 JP2007056893W WO2007114262A1 WO 2007114262 A1 WO2007114262 A1 WO 2007114262A1 JP 2007056893 W JP2007056893 W JP 2007056893W WO 2007114262 A1 WO2007114262 A1 WO 2007114262A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- casein
- active substance
- weight
- agents
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Definitions
- the present invention relates to nanoparticles for use in fields such as life science or medical diagnosis. More particularly, the present invention relates to casein nanoparticles containing an active substance.
- Fine particle materials are expected to be widely used in biotechnology.
- the application of nanoparticulate materials created by the advancement of nanotechnology to biotechnology and medical treatment has been actively studied, and many research results have been reported.
- Non-Patent Document 1 various materials such as ultra-fine emulsification and ribosome are being studied (for example, Non-Patent Document 1).
- the surfactants used for emulsification have safety concerns and are The structure formation by the complex is also less stable than the covalent bond.
- Natural polymers show the same structural stability as synthetic polymers, but also have the advantage of being a DDS carrier that is much safer than synthetic polymers.
- the difficulty of natural polymer carriers compared to synthetic polymers is the method of particle preparation. As a method for producing natural high-molecular particles, spray drying, freeze-drying, and jet mill can be used. In most cases, the particle size is micron, and it is difficult to control the size.
- Patent Document 1 proposes a solid preparation having a multi-core structure containing an active compound.
- the force particle size is 5 to 3000 m.
- Patent Document 2 proposes a nanoparticle transdermal absorbent using a polymer material. This is an emulsion using a surfactant, and as mentioned above, it is safe and stable. There are concerns.
- Patent Document 3 describes spherical protein particles, but the particle size as a composition containing a drug is 1 ⁇ m or more.
- the polymer nanoparticles known so far, including those mentioned above, are not limited to synthetic polymers, and even natural polymers may contain surfactants, polymerizable monomers, chemicals, There is a concern about safety because it uses a crosslinking agent.
- Casein is a protein that is insoluble in water contained in milk. Since the hydrophobic part faces the outside, 10-100 caseins gather as soon as the aggregate is formed, forming sub micelles of about 20 nm, and further 100-1000 caseins gather to form 90-150 nm. Casein micelles are formed. Casein micelles further gather to form a micelle aggregate of about 500 nm. Therefore, the size of casein micelles is agglomerated when a salt such as sodium or magnesium is added, or when the pH is acidified.
- a salt such as sodium or magnesium
- Non-Patent Document 1 Mitsuhiro Nishida, Frederance Journal, November, 17 (2005)
- Patent Document 1 Japanese Patent Laid-Open No. 2002-204673
- Patent Document 2 Japanese Patent Laid-Open No. 2002-308728
- Patent Document 3 Japanese Translation of Special Publication 2005-500304 Disclosure of the invention
- An object of the present invention is to solve the problems of the prior art described above. That is, the present invention provides a nanoparticle that can be produced without using a surfactant or a synthetic polymer, can control the size, is acidic and stable, and further contains an active substance, and a method for producing the nanoparticle. It was set as a problem to be solved.
- the present inventors have mixed casein with a basic aqueous medium having a pH of 8 or more and less than pH 11, added at least one active substance, and the resulting solution has a pH of 3 It was found that by injecting into an acidic aqueous medium of .5 to 7.5, or by lowering the solution to a pH that is more than pH 1 away from the isoelectric point, nanoparticles containing the active substance can be produced. It came to be completed.
- nanoparticles produced by the following steps (a) to (c) and having an average particle size of lOnm or more and less than 300 nm including an active substance.
- step (b) adding at least one active substance to the solution obtained in step (a);
- step (c) Step of injecting the solution obtained in step (b) into an acidic aqueous medium having a pH of 3.5 to 7.5:
- casein nanoparticles produced by the following steps (a) to (c) and having an average particle size of lOnm or more and less than 50 nm encapsulating an active substance.
- step (b) adding at least one active substance to the solution obtained in step (a);
- step (c) A step of lowering the pH of the solution obtained in step (b) to a pH separated from the isoelectric point by at least pH 1 while stirring the solution:
- the active substance is an ionic substance or a fat-soluble substance.
- the active substance is a cosmetic ingredient, a functional food ingredient, or a pharmaceutical ingredient.
- the cosmetic ingredients include moisturizers, whitening agents, hair growth agents, hair nourishing agents, hair growth agents, anti-whitening agents, anti-aging agents, antioxidants, collagen synthesis promoters, anti-wrinkle agents, Ki And vitamins, UV absorbers, fragrances, pigments, antiperspirants, cooling agents, warming agents, melanin inhibitors, melanocyte activators, cleansing agents, slimming agents.
- Ingredients for dietary foods can include vitamins, minerals, antioxidants, anti-stress agents, nutritional supplements, amino acids, carotenoids, fruit and plant extracts, and pharmaceutical ingredients include hair restorers, hair nourishing agents, cosmetics.
- Hair agent Antibacterial agent, Anticancer agent, Anti-inflammatory agent, Antiallergic agent, Hormone agent, Antithrombotic agent, Immunosuppressant agent, Skin disease treatment agent, Antifungal agent, Nucleic acid agent, Anesthetic agent, Antipyretic agent, Analgesic agent, Antipruritic agent, Anti-edema agent, antitussive agent, antiepileptic agent, anti-parkinsonian agent, hypnotic sedative agent, anxiolytic agent, stimulant agent, neuropsychiatric agent, muscle relaxant agent, antidepressant agent, general cold agent, autonomic nervous system agent , Antispasmodic, sweating agent, antiperspirant, Cardiac agent, arrhythmia agent, antiarrhythmic agent, vasoconstrictor, vasodilator, antiarrhythmic agent, antihypertensive agent, antidiabetic agent, hyperlipidemic agent, respiratory stimulant, antitussive agent, vitamin agent, parasitic skin Examples thereof include a disease agent,
- the casein nanoparticles of the present invention contain 0.1 to:% LOO weight% active substance, based on the weight of casein.
- step (b) a solution of the active substance dissolved in water or an organic solvent miscible with water at least 10% by weight is added.
- an organic solvent that is miscible with at least 10% by weight of water from 0.1 to: LOO% by weight, based on the weight of the basic aqueous medium, is added.
- step (b) an aqueous ribosome dispersion encapsulating the active substance is added.
- 0.1 to: LOO wt% of the active substance is encapsulated relative to the weight of casein.
- the added liposomes are added! RU
- step (b) a cyclodextrin solution of the active substance is added.
- 0.1 to: LOO wt% of cyclodextrin is added to the weight of casein.
- 0.1 to: LOO wt% lipid is added to the weight of casein
- another type protein of 0.1 to LOO% by weight is added to the weight of casein.
- 0.1 to: L00% by weight of cationic or cationic polysaccharide is added to the weight of casein.
- 0.1 to L00% by weight of cationic protein or key protein is added to the weight of casein! RU
- a drug delivery agent comprising the casein nanoparticles of the present invention described above.
- the drug delivery agent is used as a transdermal absorption agent, a topical therapeutic agent, an oral therapeutic agent, a cosmetic, a functional food, or a supplement.
- ethanol contained in the drug delivery agent is 20% or less.
- the drug delivery agent includes an additive.
- the additive is one or more humectants, softeners, transdermal absorption enhancers, preservatives, dyes, fragrances, or pH modifiers.
- step (b) adding at least one active substance to the solution obtained in step (a);
- step (c) Step of injecting the solution obtained in step (b) into an acidic aqueous medium having a pH of 3.5 to 7.5:
- step (b) adding at least one active substance to the solution obtained in step (a);
- step (c) A step of lowering the pH of the solution obtained in step (b) to a pH separated from the isoelectric point by at least pH 1 while stirring the solution:
- the present invention is a casein nanoparticle having an average particle size of lOnm or more and less than 300 nm encapsulating an active substance, which is produced by the following steps (a) to (c).
- step (b) adding at least one active substance to the solution obtained in step (a);
- step (c) Injecting the solution obtained in step (b) into an acidic aqueous medium having a pH of 3.5 to 7.5, or stirring the solution obtained in step (b), the pH of the solution is adjusted to the isoelectricity of casein. Lowering to a pH that is more than pHl away from the point:
- casein nanoparticles of a desired size can be produced. It was also found that the active substance can be encapsulated in the casein nanoparticles by utilizing the interaction between the fat-soluble active substance and the casein hydrophobic portion. Furthermore, it was found that these particles exist stably in an aqueous solution.
- ClogP is preferably larger than 0, more preferably ClogP is 1 or more, and further preferably CLogP is 3 or more.
- mixed particles of casein and an ionic polysaccharide or another type of ionic protein are mixed particles of casein and an ionic polysaccharide or another type of ionic protein
- nanoparticles encapsulating a highly safe active substance without using a surfactant or a synthetic polymer can be produced.
- the average particle size of the casein nanoparticles of the present invention is usually lOnm or more and less than 300 nm, preferably 10 to: LOOnm, and more preferably 10 to 50 nm.
- the casein nanoparticles of the present invention contain at least one active substance.
- the amount of the active substance is not particularly limited, it generally contains 0.1 to L00% by weight of the active substance relative to the weight of casein.
- casein used in the present invention is not particularly limited, and it may be derived from milk or bean.
- ⁇ -casein, 13-casein, ⁇ -casein, ⁇ -casein and mixtures thereof Things can be used.
- Genetically modified organisms can also be used.
- it can be used in the form of force zein sodium.
- Casein can be used alone or in combination of two or more.
- casein is mixed with a basic aqueous medium solution.
- a method of injecting into an acidic aqueous medium and a method of mixing casein with a basic aqueous medium solution and lowering the pH while stirring.
- the temperature of the aqueous medium can be appropriately set, but it can be normally 0 ° C to 80 ° C, preferably 25 ° C force can also be 60 ° C.
- the stirring speed is a force that can be appropriately set.
- lOOrpm can be set to 3000rpm, and preferably 200rpm to 2000rpm.
- the temperature of the basic aqueous medium can be set as appropriate, but typically, the 0 ° C force can also be 80 ° C, and preferably 25 ° C to 70 ° C.
- the stirring speed is a force that can be appropriately set. Typically, lOOrpm can be set to 3000 rpm, and preferably 200 rpm to 2000 rpm.
- aqueous medium used in the present invention an organic acid or base, an inorganic acid or inorganic base aqueous solution, or a buffer solution can be used.
- the concentration of the aqueous medium used in the present invention is preferably about 10 mM force and about 500 mM. More preferably, it is about 10 mM to about 200 mM.
- the pH of the basic aqueous medium used in the present invention is preferably 8 or more and less than 11, more preferably 9 or more and less than 11. More preferably, the pH is 9.5 to 10.5. If the pH is too high, there is a concern about hydrolysis and handling! /, and the above range is preferred.
- the temperature at which casein is mixed with a basic aqueous medium having a pH of 8 or more is preferably 0 to 80 ° C, and more preferably 10 to 60 ° C. More preferably, it is 20 to 40 ° C.
- the pH of the acidic aqueous medium used in the present invention is preferably 3.5 to 7.5. More preferably the pH is 4-6. More preferably, it is 5-6. When the pH is 3 or less, the particle size tends to increase.
- the preferred pH after the lowering is pH 8 from 1 or more away from the isoelectric point.
- the type of the active substance used in the present invention can be selected from, for example, cosmetic ingredients or pharmaceutical ingredients.
- cosmetic ingredients include moisturizers, whitening agents, hair growth agents, hair nourishing agents, hair growth agents, anti-whitening agents, anti-aging agents, antioxidants, collagen synthesis accelerators, anti-wrinkle agents, anti-acne agents, Vitamins, UV absorbers, fragrances, pigments, antiperspirants, cooling agents, warming agents, melanin production inhibitors, melanocyte activators, cleansing agents, slimming agents and the like can be mentioned.
- Ingredients for functional foods include vitamins, minerals, antioxidants, anti-stress agents, nutritional supplements, amino acids, carotenoids, fruit and plant extracts.
- Pharmaceutical components include hair restorers, hair nourishing agents, hair growth agents, antibiotics, anticancer agents, anti-inflammatory agents, antiallergic agents, hormonal agents, antithrombotic agents, immunosuppressive agents, skin disease therapeutic agents, antifungal agents, nucleic acids Medicine, anesthetic, antipyretic, analgesic, antipruritic, antiedema, antitussive heel, antiepileptic, antiparkinsonian, hypnotic sedative, anxiolytic, stimulant, neuropsychiatric, muscle relaxant, Antidepressant, General cold drug, Autonomic nervous system agent, Antispasmodic agent, Antiperspirant, Antiperspirant, Cardiotonic agent, Arrhythmic agent, Antiarrhythmic agent, Vasoconstrictor, Vasodilator, Antiarrhythmic agent, Antihypertensive agent, Diabetes Examples include therapeutic agents, high-fat plasma agents, respiratory stimulants, antitussives, vitamins, parasitic skin disease agents, homeostatic agents, polypeptides, hormones,
- moisturizers used in the present invention are not limited to these compounds. Examples include hyaluronic acid, ceramide, lipidine, isoflavone, amino acid, collagen and the like.
- the above moisturizing may be used alone,
- Two or more kinds can be used in combination.
- whitening agent used in the present invention examples include vitamin C derivatives, rhodium, idroquinones, arbutin, lucinol, and ellagic acid.
- the above-described whitening components may be used alone or in combination of two or more.
- Anti-aging agents used in the present invention * Specific examples are listed as antioxidants, but the present invention is not limited to these compounds. Carotenes, retinoic acid, retinol, vitamin C derivatives, strength rice, staxanthin, tretinoin, vitamin E and its derivatives, sesamin, hypolipoic acid, coenzyme Q 10, flavonoids, etc.
- the above-mentioned anti-aging agent 'antioxidant may be used alone or in combination of two or more.
- anti-acne agents used in the present invention is not limited to these compounds in the present invention.
- the above-mentioned anti-acne agents may be used alone or in combination of two or more.
- Fluoropyrimidine antimetabolites such as 5-fluorouracil (5FU), tegafur, doxyfluridine, force pecitabine); antibiotics (such as mitomycin (MMC) and adriacin (DXR)); purine antimetabolites (such as methotrexate) Antifolate antimetabolites, mercaptopurines, etc.); active metabolites of vitamin A (antimetabolites such as hydroxycarbamide, tretinoin, tamibarotene, etc.); molecular targeting drugs (such as Herceptin-N-Mesylate); Bribratin, Randa (CDDP), Paraplatin (CB DC), Elprat (Oxa), Axpra, etc .; Plant alkaloid drugs (Topotecin, Campto (CPT), Taxol (PTX), Taxotere (DTX),
- Mediator release inhibitors such as sodium cromoglycate and tralast, histamine HI-antagonists such as ketotifen fumarate and azelastine hydrochloride, thromboxane inhibitors such as ozadarel hydrochloride, leukotriene antagonists such as pranlukast, tosylic acid Examples include suplatast.
- One antiallergic agent described above may be used alone or in combination of two or more.
- immunosuppressant used in the present invention is listed, but the present invention is not limited to these compounds. Rapamycin, tacrolimus, cyclosporine, predo-zolone, methylpredo-zolone, mofethyl mycophenolate, azathioprine, mizoribine and the like.
- the above immunosuppressive agents may be used alone or in combination of two or more.
- the type of hair-restoring ingredients used in the present invention is not particularly limited, and for example, cosmetic ingredients or pharmaceutical ingredient strengths can be selected.
- specific examples of the hair-growth component encapsulated in protein nanoparticles include glycyrrhetinic acid or a derivative thereof, glycyrrhizic acid or a derivative thereof, hinokitiol, vitamin E or a derivative thereof, vitamin C derivative, 6-benzylaminopurine, Nicotinamide, benzyl nicotinate, tocopherol nicotinate, nicotinic acid j8-butoxy ester, isopropylmethylphenol, pentadecanoic acid or its derivatives, cephalatin, finasteride, t-flavanone, antioxidants such as carotenoids and quinine Etulestradiol, pantol alcohol, pantotellyl ether, minoxidil or its analogs, calpe chloride, adenosine and the
- the above hair-growth ingredients may be used alone or in combination of two or more.
- organic solvents that are miscible with water at least 10% by weight used in the present invention are listed, but the present invention is not limited to these compounds.
- Water-soluble organic solvents such as ethanol, isopropanol, ethylene glycol, glycerin, acetone and THF are preferred.
- the active substance can be added as a ribosome aqueous dispersion containing the active substance.
- lipids for forming ribosomes used in the present invention are not limited to these compounds in the present invention. Examples include egg yolk lecithin, soybean lecithin, egg yolk phosphatidylcholine, dipalmitoyl phosphatidylcholine, dimyristoyl phosphatidylcholine, and the like.
- phosphatidylserines, phosphatidylethanolamines, cholesterol, etc. may be included.
- lipids used in the present invention is not limited to these compounds in the present invention.
- Phosphatidylcholine (lecithin) phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, diphosphatidylglycerol, sphingosines, ceramide, oleic acid, linoleic acid, linolenic acid, palmitic acid, myristic acid, stearic acid, soybean oil, olive oil Oil, squalane, and the like.
- the type of another type of protein used in the present invention is not particularly limited, but it is preferable to use a protein having a molecular weight of about 10,000 to 1,000,000.
- the origin of the protein is not particularly limited, but it is preferable to use a human-derived protein. List specific examples of proteins In the present invention, the present invention is not limited to these compounds. Collagen, gelatin, albumin, transferrin, fibrin, fibrinogen, globulin, fibrin, laminin, fibronectin, or vitronectin can be used.
- the origin of the protein is not particularly limited, and any of cows, pigs, fish, and recombinants can be used. Of these, gelatin and albumin are preferred.
- the eron polysaccharide used in the present invention is a polysaccharide having an acidic polar group such as a carboxyl group, a sulfate group or a phosphate group. Specific examples are listed below, but the present invention is not limited to these compounds. Examples thereof include chondroitin sulfate, dextran sulfate, carboxymethyl dextran, alginic acid, pectin, carrageenan, fucoidan, agaropectin, volphilan, caraja gum, dielan gum, xanthan gum, and hyaluronic acid.
- an acidic polar group such as a carboxyl group, a sulfate group or a phosphate group. Specific examples are listed below, but the present invention is not limited to these compounds. Examples thereof include chondroitin sulfate, dextran sulfate, carboxymethyl dextran, alginic acid, pectin, carrageenan, fuco
- the cationic polysaccharide used in the present invention is a polysaccharide having a basic polar group such as an amino group. Specific examples are listed below, but the present invention is not limited to these compounds. Examples include dalcosamines such as chitin and chitosan, which contain galactosamine as a constituent monosaccharide.
- the key protein used in the present invention is a protein or lipoprotein whose isoelectric point is on the basic side of physiological pH. Specific examples are listed, but the present invention is not limited to these compounds. Examples include polyglutamic acid, polyaspartic acid, cytochrome C, ribonuclease, trypsinogen, chymotrypsinogen, and OC-chymotrypsin.
- the cationic proteins used in the present invention are proteins and lipoproteins whose isoelectric point is on the acidic side of physiological pH. Power to List Specific Examples In the present invention, the present invention is not limited to these compounds. Examples include polylysine, polyarginine, histone, protamine, and ovalbumin.
- the ionic protein and polysaccharide used in the present invention have a charge opposite to that of the active substance, and the addition amount is 0.1 to 100% by weight relative to the weight of casein. I prefer to be there!
- the casein nanoparticle of the present invention contains an active substance therein, and the casein nanoparticle containing such an active substance can be used by being administered to a disease site. That is, the casein nanoparticle of the present invention is useful as a drug delivery agent.
- the use of the drug delivery agent is not particularly limited.
- Topical therapeutic agents topical therapeutic agents, oral therapeutic agents, cosmetics, supplements and the like.
- the drug delivery agent preferably contains 0.01 to 50% by weight of protein nanoparticles, more preferably 0.1 to: LO% by weight of protein nanoparticles.
- ethanol contained in the drug delivery agent is 20% or less. More preferably, it is 10% or less.
- the drug delivery agent may contain an additive.
- an additive A moisturizer, a softener, a percutaneous absorption enhancer, antiseptic
- humectants that can be used in the present invention.
- the present invention is not limited to these compounds. Examples include agar, diglycerin, distearyl dimethyl hectorite, butylene glycol, polyethylene glycol, propylene glycol, sodium hyaluronate, hexylene glycol, octyne extract and petrolatum.
- the softening agent is listed, but the present invention is not limited to these compounds.
- Glycerin, mineral oil, emollient ingredients e.g., isopropyl isostearate, polyglyceryl isostearate, isotridecyl isononanoate, octyl isononanoate, oleic acid, glyceryl oleate, cocoa butter, cholesterol, mixed fatty acid triglyceride, dioctyl succinate, acetic acid Sucrose stearate, cyclopentacyclohexane, sucrose distearate, octyl palmitate, octyl hydroxystearate, aralkyl behenate, sucrose polybehenate, polymethylsilsesquioxane, myristyl alcohol, cetyl myristate, myristyl myristate, laurin Acid hexyl).
- emollient ingredients e
- transdermal absorption enhancer examples include It is not limited. Ethanol, isopropyl myristate, citrate, squalane, oleic acid, menthol, N-methyl-2-pyrrolidone, jetyl adipate, diisopropyl adipate, jetyl sebacate, diisopropyl sebacate, isopropyl palmitate, isopropyl oleate, Examples include otatildodecyl oleate, isostearyl alcohol, 2-octyldodecanol, urea, vegetable oils and animal oils.
- preservative examples include benzoic acid, sodium benzoate, ethylparaben, potassium sorbate, sodium sorbate, sorbic acid, sodium dehydroacetate, and methylparaben.
- coloring agent examples include kaolin, carmine, gundiio, acid chrome, and iron oxide.
- pH adjusting agent examples include sodium citrate, sodium acetate, sodium hydroxide, potassium hydroxide, and phosphoric acid.
- a preferred method for administering the casein nanoparticles of the present invention is transdermal transmucosal absorption. Specific examples are listed as administration methods, but the present invention is not limited to these.
- Solution for external use poultice, coating agent, wiping agent, bath agent, disinfectant, ointment, gel, cream, plaster, poultice, plaster, wound covering, wound covering-gauze type, hemostasis Agents, adhesives, adhesive tapes, transdermal adhesive tapes, wound protection agents, aerosols, lotions, tonics, liniments, emulsions, suspensions, saturants, tinctures, powders, foams, cosmetics Water, massage cream, nutrition cream, pack, sheet-type skin external preparation, skin adhesive type cosmetics, lipstick, makeup base, foundation, shampoo, rinse, body soap, sarcophagus, bath preparation, nail preparation, nose Examples include mucosa, oral mucosa, rectal mucosa, vaginal mucosa, ophthalmic muco
- the dosage of the casein nanoparticles of the present invention can be set appropriately according to the patient's weight, disease state, etc. Generally, about 10 g to 100 mgZkg per administration. Preferably, about 20 / ⁇ to 50 ⁇ ⁇ ⁇ 3 ⁇ 4 can be administered.
- the following examples further illustrate the present invention in detail but are not to be construed to limit the scope thereof.
- Casein milk-derived 'Wako Pure Chemical Industries, Ltd. 20 mg, chondroitin sulfate-C (Wako Pure Chemical Industries, Ltd.) 2 mg is mixed with pHIO phosphorus and 50 mM acid buffer lmL. Dissolve 5 mg of Tocopherol (manufactured by Wako Pure Chemical Industries) in 1 mL of ethanol. After mixing these two solutions and applying ultrasound, lmL was injected into 10 mL of phosphate buffered water at pH 5 and 200 mM using a microsyringe under stirring conditions of 40 ° C and 800 rpm. As a result, casein nanoparticles were obtained.
- the average particle size of the above particles was 57 nm as measured using a light scattering photometer and Nanotrack manufactured by Nikkiso Co., Ltd.
- the average particle size of the above particles was 60 nm as measured using a light scattering photometer and Nanotrack manufactured by Nikkiso Co., Ltd.
- Casein milk-derived 'Wako Pure Chemical Industries, Ltd. 20mg, protamine sulfate (Wako Pure Chemical Industries, Ltd.) lmg is mixed with pH10, 50mM phosphate buffer ImL. 1 mg of ⁇ -lipoic acid is dissolved in ion-exchanged water. When these two solutions were mixed and ImL was injected into 10 mL of phosphate buffer at pH 5 and 200 mM using a microsyringe with external stirring at 40 ° C and 800 rpm, force zein nanoparticles were obtained. It was.
- the average particle size of the above particles was 48 nm as measured using a light scattering photometer and Nanotrack manufactured by Nikkiso Co., Ltd.
- the average particle size of the above particles was 32 nm as measured using a light scattering photometer and Nanotrack manufactured by Nikkiso Co., Ltd.
- Casein milk-derived 'Wako Pure Chemical Industries, Ltd.
- lOOmg is mixed with 10mL of pH10, 50mM phosphate buffer.
- hydrochloric acid was added with stirring to adjust the pH to 7, casein nanoparticle was obtained.
- the average particle size of the above particles was 23 nm as measured using a light scattering photometer and Nanotrack manufactured by Nikkiso Co., Ltd.
- the average particle size of the above particles was 27 nm as measured using a light scattering photometer and Nanotrack manufactured by Nikkiso Co., Ltd.
- casein sodium milk-derived 'Wako Pure Chemical Industries, Ltd.
- 10 mL of pH 10 and 25 mM phosphate buffer Dissolve 1.7 mg of hinokitiol in O.lmL of ethanol.
- hydrochloric acid was added with stirring to adjust the pH to 7, casein nanoparticles were obtained.
- the average particle size of the above particles was 16 nm as measured using a light scattering photometer and Nanotrack manufactured by Nikkiso Co., Ltd.
- the average particle size of the above particles was 327 nm as measured using a light scattering photometer and Nanotrack manufactured by Nikkiso Co., Ltd.
- Casein milk-derived 'Wako Pure Chemical Industries, Ltd.
- lOOmg is mixed with pH10, 50mM phosphate buffer lOmL.
- hydrochloric acid was added with stirring to adjust the pH to 4, the solution became cloudy and aggregated.
- Test Example 1 The average particle size of the above particles was 485 nm as measured using a light scattering photometer and Nanotrack manufactured by Nikkiso Co., Ltd. [0077] Test Example 1
- the nanoparticles of Examples 5 to 8 were centrifuged using Hitachi Koki's ultracentrifuge CS100GXL, and the HPLC analysis result of the supernatant liquid and the amount of added force were obtained. The entrapment ratio of the active substance contained in the particles was determined. It was.
- the casein nanoparticles of the present invention use casein that does not have a problem in biocompatibility without using a surfactant or a synthetic polymer, and thus has high safety.
- the casein nanoparticles of the present invention can be controlled in size, and are acidic and stable, so that the absorption rate and feeling of use can be improved.
- the active substance since the active substance is encapsulated, the active substance that is insoluble or only partially soluble in water can be stably dispersed in water.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Birds (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/295,287 US20090280148A1 (en) | 2006-03-29 | 2007-03-29 | Casein nanoparticle |
CN2007800121752A CN101415395B (zh) | 2006-03-29 | 2007-03-29 | 酪蛋白纳米粒子 |
JP2008508615A JP5118019B2 (ja) | 2006-03-29 | 2007-03-29 | カゼインナノ粒子 |
EP07740331A EP2011472A4 (en) | 2006-03-29 | 2007-03-29 | CASEIN-NANOPARTICLES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006090205 | 2006-03-29 | ||
JP2006-090205 | 2006-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007114262A1 true WO2007114262A1 (ja) | 2007-10-11 |
Family
ID=38563530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/056893 WO2007114262A1 (ja) | 2006-03-29 | 2007-03-29 | カゼインナノ粒子 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090280148A1 (ja) |
EP (1) | EP2011472A4 (ja) |
JP (1) | JP5118019B2 (ja) |
KR (1) | KR20080111033A (ja) |
CN (1) | CN101415395B (ja) |
WO (1) | WO2007114262A1 (ja) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008201767A (ja) * | 2007-01-24 | 2008-09-04 | Fujifilm Corp | 頭髪用組成物 |
JP2008255020A (ja) * | 2007-04-02 | 2008-10-23 | Fujifilm Corp | 抗老化皮膚外用剤 |
EP1997477A1 (en) * | 2007-05-31 | 2008-12-03 | FUJIFILM Corporation | Anti-acne skin agent for external use |
JP2009096787A (ja) * | 2007-10-19 | 2009-05-07 | Fujifilm Corp | 血行促進剤を内包した水分散可能なナノ粒子 |
JP2009120555A (ja) * | 2007-11-16 | 2009-06-04 | Fujifilm Corp | 殺菌剤を内包した水分散可能なナノ粒子 |
JP2009173610A (ja) * | 2008-01-28 | 2009-08-06 | Fujifilm Corp | タンパク質ナノ粒子 |
JP2009249370A (ja) * | 2008-04-11 | 2009-10-29 | Fujifilm Corp | タンパク質ナノ粒子 |
JP2009269844A (ja) * | 2008-05-02 | 2009-11-19 | Fujifilm Corp | 頭髪用組成物 |
JP2010006721A (ja) * | 2008-06-25 | 2010-01-14 | Fujifilm Corp | タンパク質ナノ粒子を含むヘアトリートメント組成物 |
JP2010132609A (ja) * | 2008-12-05 | 2010-06-17 | Fujifilm Corp | カゼインナノ粒子 |
WO2011078154A1 (ja) * | 2009-12-21 | 2011-06-30 | 富士フイルム株式会社 | 頭髪用化粧料の製造方法 |
JP2011519932A (ja) * | 2008-05-09 | 2011-07-14 | サウス ダコタ ステート ユニバーシティー | 非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用 |
US8303942B2 (en) | 2007-01-24 | 2012-11-06 | Fujifilm Corporation | Composition for hair |
JP2013520191A (ja) * | 2010-02-26 | 2013-06-06 | ウニベルシダ デ ナバーラ | 化合物をカプセル化するためのナノ粒子、その調製およびその使用 |
JP2013530128A (ja) * | 2010-04-13 | 2013-07-25 | 株式会社アモーレパシフィック | 経皮吸収用高分子‐リポソームナノ複合体組成物及びその製造方法 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008266179A (ja) * | 2007-04-19 | 2008-11-06 | Fujifilm Corp | 経肺用組成物 |
CA2906594C (en) | 2013-03-15 | 2019-01-08 | Leading Edge Innovations, LLC | Substantially surfactant-free, submicron dispersions of hydrophobic agents containing high levels of water miscible solvent |
US20140322428A1 (en) | 2013-03-15 | 2014-10-30 | Leading Edge Innovations, LLC | Compositions having an oil-in-water dispersion of submicron particles to enhance foods and beverages |
CN104667289B (zh) * | 2014-01-28 | 2018-08-14 | 暨南大学 | 一种抗肿瘤药物载体及其使用方法 |
CN104151841B (zh) * | 2014-07-28 | 2016-04-06 | 陕西科技大学 | 一种多层中空酪素基亚微米复合微胶囊及其制备方法 |
EP3705176A4 (en) * | 2017-11-02 | 2021-08-25 | San-Ei Gen F.F.I., INC. | PROCESS FOR THE PRODUCTION OF WATER SOLUBLE OR WATER DISPERSIBLE MICRO PARTICLES, USE OR USE OF THESE AS A SUBSTITUTE WITH AN EMULSIFYING FUNCTION, PROCESS FOR THE PRODUCTION OF AN EMULSION, PROCESS FOR THE PRODUCTION OF FOOD AND CONTAINING FOOD AN EMULSION |
CN109757723B (zh) * | 2019-01-25 | 2022-07-01 | 集美大学 | 一种含岩藻黄醇的视力保护功能食品及其制备方法 |
CN109588721B (zh) * | 2019-01-25 | 2022-10-04 | 集美大学 | 一种类胡萝卜素-蛋白微粒及其制备方法和应用 |
CN109588711B (zh) * | 2019-01-25 | 2022-10-04 | 集美大学 | 一种岩藻黄素-牡蛎肽纳米颗粒及其制备方法和应用 |
CN109588712B (zh) * | 2019-01-28 | 2022-10-04 | 集美大学 | 一种岩藻黄素-蛋白微粒及其制备方法和应用 |
CN109588713B (zh) * | 2019-01-28 | 2022-10-04 | 集美大学 | 一种岩藻黄醇-蛋白微粒及其制备方法和应用 |
CN111012760B (zh) * | 2019-12-28 | 2021-10-26 | 复旦大学 | 负载疏水药物、营养物的酪蛋白/阴离子多糖纳米粒子及其制备方法 |
CN115501181A (zh) * | 2021-06-07 | 2022-12-23 | 武汉科福新药有限责任公司 | 一种纳多洛尔柔性纳米凝胶乳剂及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000103733A (ja) * | 1998-09-14 | 2000-04-11 | Basf Ag | 安定なリコピン粉末製剤、安定なリコピン水性分散液、それらの製法、それらの使用およびそれらを含有する栄養補助剤、動物飼料、食品、および医薬品および化粧品 |
JP2002204673A (ja) | 2000-08-30 | 2002-07-23 | Basf Ag | マルチコア構造を有する固体調製物 |
JP2002255931A (ja) * | 2000-11-29 | 2002-09-11 | Basf Ag | 水溶性、水難溶性または水不溶性活性化合物の固体調製物の製造 |
JP2002308728A (ja) | 2001-04-13 | 2002-10-23 | Pacific Corp | 高分子ナノ粒子を用いた経皮吸収剤及びこれを含有する外用剤 |
WO2003066019A2 (de) * | 2002-02-08 | 2003-08-14 | Abbott Gmbh & Co. Kg | Verfahren zur herstellung wasserdispergierbarer trockenpulver von in wasser schwer löslichen verbindungen |
WO2003080034A2 (de) * | 2002-03-27 | 2003-10-02 | Pharmatech Gmbh | Verfahren zur herstellung und anwendung von mikro- und nanoteilchen durch aufbauende mikronisation |
JP2005500304A (ja) | 2001-06-21 | 2005-01-06 | アルタス バイオロジックス インコーポレイテッド | 球状タンパク質粒子およびそれらの作製方法および使用方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3995070A (en) * | 1971-05-26 | 1976-11-30 | Morinaga Milk Industry Co., Ltd. | Process for preparing a casein micelle |
GB8522963D0 (en) * | 1985-09-17 | 1985-10-23 | Biocompatibles Ltd | Microcapsules |
US5173322A (en) * | 1991-09-16 | 1992-12-22 | Nestec S.A. | Reformed casein micelles |
ES2068762B1 (es) * | 1993-07-21 | 1995-12-01 | Lipotec Sa | Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion. |
GB9726916D0 (en) * | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
JP3037654B2 (ja) * | 1998-02-05 | 2000-04-24 | 全国農業協同組合連合会 | 易吸収性葉酸製剤、その製造方法及びそれを含む飼料 |
WO2000000178A1 (fr) * | 1998-06-30 | 2000-01-06 | Rohto Pharmaceutical Co., Ltd. | Compositions contenant des liposomes et/ou des emulsions et leur procede de preparation |
US20020054914A1 (en) * | 1999-02-03 | 2002-05-09 | Tulin Morcol | Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein |
DE10121982B4 (de) * | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
-
2007
- 2007-03-29 EP EP07740331A patent/EP2011472A4/en not_active Withdrawn
- 2007-03-29 CN CN2007800121752A patent/CN101415395B/zh active Active
- 2007-03-29 KR KR1020087024286A patent/KR20080111033A/ko not_active Application Discontinuation
- 2007-03-29 WO PCT/JP2007/056893 patent/WO2007114262A1/ja active Application Filing
- 2007-03-29 JP JP2008508615A patent/JP5118019B2/ja active Active
- 2007-03-29 US US12/295,287 patent/US20090280148A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000103733A (ja) * | 1998-09-14 | 2000-04-11 | Basf Ag | 安定なリコピン粉末製剤、安定なリコピン水性分散液、それらの製法、それらの使用およびそれらを含有する栄養補助剤、動物飼料、食品、および医薬品および化粧品 |
JP2002204673A (ja) | 2000-08-30 | 2002-07-23 | Basf Ag | マルチコア構造を有する固体調製物 |
JP2002255931A (ja) * | 2000-11-29 | 2002-09-11 | Basf Ag | 水溶性、水難溶性または水不溶性活性化合物の固体調製物の製造 |
JP2002308728A (ja) | 2001-04-13 | 2002-10-23 | Pacific Corp | 高分子ナノ粒子を用いた経皮吸収剤及びこれを含有する外用剤 |
JP2005500304A (ja) | 2001-06-21 | 2005-01-06 | アルタス バイオロジックス インコーポレイテッド | 球状タンパク質粒子およびそれらの作製方法および使用方法 |
WO2003066019A2 (de) * | 2002-02-08 | 2003-08-14 | Abbott Gmbh & Co. Kg | Verfahren zur herstellung wasserdispergierbarer trockenpulver von in wasser schwer löslichen verbindungen |
WO2003080034A2 (de) * | 2002-03-27 | 2003-10-02 | Pharmatech Gmbh | Verfahren zur herstellung und anwendung von mikro- und nanoteilchen durch aufbauende mikronisation |
Non-Patent Citations (2)
Title |
---|
MITSUHIRO NISHIDA, FRAGRANCE JOURNAL, vol. 17, November 2005 (2005-11-01) |
See also references of EP2011472A4 |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8303942B2 (en) | 2007-01-24 | 2012-11-06 | Fujifilm Corporation | Composition for hair |
JP2008201767A (ja) * | 2007-01-24 | 2008-09-04 | Fujifilm Corp | 頭髪用組成物 |
JP2008255020A (ja) * | 2007-04-02 | 2008-10-23 | Fujifilm Corp | 抗老化皮膚外用剤 |
EP1997477A1 (en) * | 2007-05-31 | 2008-12-03 | FUJIFILM Corporation | Anti-acne skin agent for external use |
JP2009096787A (ja) * | 2007-10-19 | 2009-05-07 | Fujifilm Corp | 血行促進剤を内包した水分散可能なナノ粒子 |
JP2009120555A (ja) * | 2007-11-16 | 2009-06-04 | Fujifilm Corp | 殺菌剤を内包した水分散可能なナノ粒子 |
JP2009173610A (ja) * | 2008-01-28 | 2009-08-06 | Fujifilm Corp | タンパク質ナノ粒子 |
JP2009249370A (ja) * | 2008-04-11 | 2009-10-29 | Fujifilm Corp | タンパク質ナノ粒子 |
JP2009269844A (ja) * | 2008-05-02 | 2009-11-19 | Fujifilm Corp | 頭髪用組成物 |
EP2113287A3 (en) * | 2008-05-02 | 2015-01-21 | FUJIFILM Corporation | Composition for hair |
JP2014177474A (ja) * | 2008-05-09 | 2014-09-25 | South Dakota State Univ | 非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用 |
JP2011519932A (ja) * | 2008-05-09 | 2011-07-14 | サウス ダコタ ステート ユニバーシティー | 非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用 |
JP2010006721A (ja) * | 2008-06-25 | 2010-01-14 | Fujifilm Corp | タンパク質ナノ粒子を含むヘアトリートメント組成物 |
JP2010132609A (ja) * | 2008-12-05 | 2010-06-17 | Fujifilm Corp | カゼインナノ粒子 |
WO2011078154A1 (ja) * | 2009-12-21 | 2011-06-30 | 富士フイルム株式会社 | 頭髪用化粧料の製造方法 |
JP2013520191A (ja) * | 2010-02-26 | 2013-06-06 | ウニベルシダ デ ナバーラ | 化合物をカプセル化するためのナノ粒子、その調製およびその使用 |
AU2011219694B2 (en) * | 2010-02-26 | 2014-12-18 | Centro Nacional De Tecnologia Y Seguridad Alimentaria, Laboratorio Del Ebro | Nanoparticles for the encapsulation of compounds, preparation thereof and use of same |
JP2013530128A (ja) * | 2010-04-13 | 2013-07-25 | 株式会社アモーレパシフィック | 経皮吸収用高分子‐リポソームナノ複合体組成物及びその製造方法 |
US9572769B2 (en) | 2010-04-13 | 2017-02-21 | Amorepacific Corporation | Polymer-liposome nanocomposite composition for percutaneous absorption, and method for preparing same |
Also Published As
Publication number | Publication date |
---|---|
JP5118019B2 (ja) | 2013-01-16 |
JPWO2007114262A1 (ja) | 2009-08-13 |
EP2011472A1 (en) | 2009-01-07 |
KR20080111033A (ko) | 2008-12-22 |
US20090280148A1 (en) | 2009-11-12 |
EP2011472A4 (en) | 2013-01-23 |
CN101415395A (zh) | 2009-04-22 |
CN101415395B (zh) | 2012-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5118019B2 (ja) | カゼインナノ粒子 | |
JP7075377B2 (ja) | 脂質及び界面活性剤の高分子集合体を含む組成物 | |
JP2007224012A (ja) | 酵素架橋したタンパク質ナノ粒子 | |
JP2010132609A (ja) | カゼインナノ粒子 | |
US9079874B2 (en) | α-Lipoic acid nanoparticles and methods for preparing thereof | |
US8303942B2 (en) | Composition for hair | |
JP2008297241A (ja) | ニキビ用皮膚外用剤 | |
JP2009173610A (ja) | タンパク質ナノ粒子 | |
JPWO2012169518A1 (ja) | 液状組成物及びそれを用いた化粧料並びに育毛剤 | |
JP2008255020A (ja) | 抗老化皮膚外用剤 | |
JP2008201767A (ja) | 頭髪用組成物 | |
JP2009249370A (ja) | タンパク質ナノ粒子 | |
JP2009040722A (ja) | 複数のタンパク質からなるカゼインナノ粒子 | |
JP2008285432A (ja) | 皮膚外用剤 | |
JP2009120555A (ja) | 殺菌剤を内包した水分散可能なナノ粒子 | |
JP2009096787A (ja) | 血行促進剤を内包した水分散可能なナノ粒子 | |
JP4974533B2 (ja) | ジスルフィド架橋したタンパク質ナノ粒子 | |
JP2008179551A (ja) | 経皮吸収製剤 | |
JP2008110926A (ja) | 水分散可能なナノ粒子 | |
JP2008266178A (ja) | 経粘膜吸収用組成物 | |
JP2009269844A (ja) | 頭髪用組成物 | |
JP7406057B2 (ja) | 外用微粒子カプセル製剤及び皮膚外用剤 | |
JP2008247814A (ja) | 美白用皮膚外用剤 | |
Katarija et al. | The review of patents on solid lipid nanoparticles | |
Mohamed Noor | Lipid-based Nanoparticles for Topical Delivery of Hair Growth Therapeutic Molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07740331 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008508615 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12295287 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087024286 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780012175.2 Country of ref document: CN |
|
REEP | Request for entry into the european phase |
Ref document number: 2007740331 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007740331 Country of ref document: EP |